Introduction {#s1}
============

Aging is the single biggest risk factor for the majority of non-communicable complex diseases, including some of those with the greatest negative impact on human health outcomes worldwide ([@bib16]). Work over the last two decades has uncovered molecular mechanisms that can be manipulated in model organisms to modulate the aging process and reduce overall disease risk in old age ([@bib18]). Many of these interventions have been linked to nutrient and energy sensing pathways, whose modulation genetically or pharmacologically mimics the effects of dietary restriction on healthy aging ([@bib19]). One classic example of a nutrient sensor linked to longevity is TORC1, which promotes anabolic processes such as protein translation to provide macromolecules for growth and proliferation while inhibiting catabolic activities such as autophagy ([@bib1]). TORC1 is activated by growth factors and amino acids, the latter of which act through sensors such as the sestrins to facilitate heterodimer formation of the Rag proteins (consisting of RagA, B, C and D in mammals), an essential step for TORC1 activation ([@bib49]). Suppression of TORC1 both genetically and pharmacologically, via rapamycin feeding, promotes longevity in multiple species from yeast to mice ([@bib32]). In contrast to TORC1, the conserved kinase AMPK is activated under low energy conditions. AMPK activation promotes catabolic processes that generate ATP, including the TCA cycle, fatty acid oxidation and autophagy ([@bib10]), and extends lifespan in *C. elegans* ([@bib4]; [@bib21]; [@bib40]) and fruit flies ([@bib55]). Given the antagonistic roles of TORC1 and AMPK in nutrient-sensing, metabolism and longevity, it is perhaps intuitive that they are mechanistically linked. Indeed, in mammals, AMPK is generally regarded as an upstream suppressor of TORC1 as it phosphorylates the TSC complex and raptor to inhibit TORC1 activity ([@bib23]; [@bib30]). Conversely, TORC1 signaling has been suggested to inhibit AMPK via p70 ribosomal protein S6 Kinase (S6K) ([@bib14]). However, much of the work elucidating how AMPK and TORC1 interact has been performed in vitro in cell culture studies and it remains unclear in multicellular organisms whether TORC1 and AMPK causally coordinate to modulate the aging process.

Here, we elucidate the relationship between AMPK and TORC1 in the modulation of aging by discovering a critical role for neuronal AMPK in lifespan extension resulting from suppression of TORC1 components in *C. elegans*. We show that neuronal TORC1 pathway activity itself is critical for healthy aging. Restoring either *raga-1* or *rsks-1* (encoding the *C. elegans* orthologue of S6 Kinase) only in neurons fully suppresses lifespan extension in animals lacking the respective TORC1 component in all other cell types. However, the downstream effectors of AMPK longevity and TORC1 longevity appear separable; constitutive activation of CREB regulated transcriptional coactivator 'CRTC'−1, which suppresses AMPK longevity, does not suppress lifespan extension by TORC1 suppression. We show that neuronal RAGA-1 regulates metabolic genes in distal tissues and critically requires UNC-64/syntaxin exocytosis to modulate systemic longevity. Using RNA-Seq and in vivo reporters, we identify mitochondrial network state as the downstream mechanism for lifespan regulation by neuronal RAGA-1. Neuronal RAGA-1 activity regulates mitochondrial networks in distal tissues cell nonautonomously and this regulation is required for the effect of neuronal RAGA-1 on the aging process. Together, our data provide key insights into the tissue-specific roles of TORC1 suppression in healthy aging and highlight the nervous system as a putative target site for future pharmacological interventions aimed at the TORC1 pathway.

Results {#s2}
=======

AMPK is required for longevity mediated by TORC1 suppression {#s2-1}
------------------------------------------------------------

AMPK is canonically regarded as an upstream suppressor of TORC1. However, whether TORC1 suppression acts downstream of the pro-longevity effects of AMPK is unknown. Loss of the TORC1 target S6 Kinase increases lifespan in *C. elegans* and mouse ([@bib52]) and results in transcriptional profiles in muscle that resemble those of active AMPK ([@bib52]). Interestingly, AMPK activity is required for lifespan extension by loss of S6K in *C. elegans* ([@bib52]), which does not support a model where AMPK acts linearly upstream of TORC1 to modulate aging.

S6K deletion has been shown to activate AMPK in both *C. elegans* and mice ([@bib52]). To examine whether the activation of AMPK is specific to RSKS-1 (S6K) or pertains more broadly to the TORC1 pathway, we assayed the phosphorylation status of AMPK upon inhibition of multiple TORC1 components in *C. elegans*. We measured AMPK activity, using antibodies targeting phosphorylation of the α catalytic subunit at threonine 172, a site in the activation loop that is a hallmark of AMPK activation ([@bib24]). This phosphorylation site is conserved in *C. elegans* on the two AMPKα subunits, AAK-1 and AAK-2 ([@bib4]) and its phosphorylation has been used to measure AMPK activity ([@bib52]). To confirm conservation, we generated animals carrying a CRISPR induced threonine-to-alanine mutation at T243 on AAK-2, the residue homologous to mammalian T172. Lysates from both CRISPR generated AAK-2(T243A) mutation animals, and *aak-2(ok524)* mutants which harbor a 408 bp deletion spanning T243, completely lose recognition by antibody targeting phosphorylated AMPK T172 ([Figure 1---figure supplement 1a](#fig1s1){ref-type="fig"}), confirming conservation of this phosphorylation event (hereafter referred to as AMPK T172 phosphorylation) and specificity of the antibody to AAK-2. RNAi against *let-363* (homolog of TOR) significantly increases AMPK T172 phosphorylation ([Figure 1---figure supplement 1b,c](#fig1s1){ref-type="fig"}) in whole worm lysates. In addition, we found significantly increased levels of AMPK T172 phosphorylation in animals carrying a null allele in *raga-1* ([Figure 1a,b](#fig1){ref-type="fig"}), a gene encoding a homologous protein to RagA, which senses amino acids and activates TORC1 ([@bib49]). Taken together, these data suggest that in *C. elegans,* AMPK is activated when TORC1 signaling is decreased.

![Neuronal AMPK is required for TORC1-mediated longevity.\
(**a, b**) AMPK T172 phosphorylation is increased in *raga-1(ok386)* null mutants compared to wild type animals. Actin levels are used as loading controls (representative immunoblot and corresponding quantification, n = 3 independent blots). Source data for [Figure 1b](#fig1){ref-type="fig"} are provided in [Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}. (**c, d**) Knockdown of (**c**) *let-363 (TOR)* (n = 3 independent biological replicates) or (**d**) *raga-1* from day 1 of adulthood extends lifespan in wild type animals (p\<0.0001), but not in *aak-2(ok524)* null mutants (n = 8 independent biological replicates). *P* values: wild type on no RNAi vs *let-363* RNAi (p\<0.0001), *aak-2(ok524)* on no RNAi vs *let-363* RNAi (p=0.0122), wild type vs *aak-2(ok524)* on *let-363* RNAi (p\<0.0001); wild type on no RNAi vs *raga-1* RNAi (p\<0.0001), *aak-2(ok524)* on no RNAi vs *raga-1* RNAi (p=0.1968). Sample size ranges between 62--115 deaths per treatment each replicate. *P* values are calculated with Log-rank (Mantel-Cox) test. Details on strains and lifespan replicates can be found in [Supplementary file 6](#supp6){ref-type="supplementary-material"}. (**e**) *raga-1(ok386)* mutants live longer than wild type (p\<0.0001). *raga-1(ok386); aak-2(ok524)* double mutant animals do not live significantly longer than *aak-2(ok524)* single mutants (p=0.9735). n = 5 independent biological replicates, sample size ranges between 90--129 deaths per treatment each replicate. *P* values are calculated with Log-rank (Mantel-Cox) test. Details on strains and lifespan replicates can be found in [Supplementary file 6](#supp6){ref-type="supplementary-material"}. (**f**) *raga-1(ok386)* mutants live longer than wild type (p\<0.0001). *raga-1(ok386)* does not extend lifespan in an *aak-2(wbm20)* \[AAK-2 (T243A)\] CRISPR-generated allele background (p=0.5354). n = 3 independent biological replicates, sample size ranges between 93--119 deaths per treatment each replicate. *P* values are calculated with Log-rank (Mantel-Cox) test. Details on strains and lifespan replicates can be found in [Supplementary file 6](#supp6){ref-type="supplementary-material"}. (**g**) At the restrictive temperature 22.5°C to induce *par-4* loss-of-function, *raga-1* RNAi from adulthood extends lifespan in wild type animals (p\<0.0001) but does not extend lifespan of *par-4(it57)* mutant animals (p=0.206). Worms were grown at 15°C until L4 stage before shifting to restrictive temperature. n = 3 independent biological replicates, sample size 68--115 deaths per treatment each replicate. *P* values are calculated with Log-rank (Mantel-Cox) test. Details on strains and lifespan replicates can be found in [Supplementary file 6](#supp6){ref-type="supplementary-material"}. (**h**) *raga-1(ok386)* null allele extends lifespan in animals expressing the non-phosphorylatable CRTC-1^S76A,\ S179A^ driven by a pan-neuronal *rab-3* promoter (p\<0.0001). n = 3 independent biological replicates; sample size ranges between 90--121 deaths per treatment each replicate. *P* values are calculated with Log-rank (Mantel-Cox) test. Details on strains and lifespan replicates can be found in [Supplementary file 6](#supp6){ref-type="supplementary-material"}. (**i**) *raga-1* RNAi from adulthood extends median lifespan of animals overexpressing *aak-2^aa1-321^* driven by the ubiquitous *sur-5* promoter in *aak-2* mutant background (p\<0.0001). n = 3 independent biological replicates; sample size ranges between 78--109 deaths per treatment. *P* values are calculated with Log-rank (Mantel-Cox) test. Details on strains and lifespan replicates can be found in [Supplementary file 6](#supp6){ref-type="supplementary-material"}. (**j, k**) *raga-1* RNAi from adulthood does not extend median lifespan of animals overexpressing *aak-2 ^aa1-321^* driven by (**j**) an intestine-specific *gly-19* promoter (p=0.0342) or (**k**) a muscle-specific *myo-3* promoter in *aak-2* mutant background (p=0.9827). n = 3 independent biological replicates; sample size ranges between 72--102 (intestine) and 44--107 (muscle) deaths per treatment each replicate. *P* values are calculated with Log-rank (Mantel-Cox) test. Details on strains and lifespan replicates can be found in [Supplementary file 6](#supp6){ref-type="supplementary-material"}. (**l**) *raga-1* RNAi from adulthood can extend median lifespan of animals overexpressing *aak-2 ^aa1-321^* driven by the pan-neuronal *rab-3* promoter in an *aak-2* mutant background (p\<0.0001). n = 4 independent biological replicates, sample size ranges between 66--117 deaths per treatment each replicate. *P* values are calculated with Log-rank (Mantel-Cox) test. Details on strains and lifespan replicates can be found in [Supplementary file 6](#supp6){ref-type="supplementary-material"}.\
10.7554/eLife.49158.004Figure 1---source data 1.[Figure 1b](#fig1){ref-type="fig"} AMPK activity is increased in raga-1 mutants.](elife-49158-fig1){#fig1}

We next tested whether AMPK activity is required for longevity resulting from TORC1 suppression. Adult-onset RNAi of *let-363* (TOR) or *raga-1* extended median lifespan by 20% in wild type animals, but this effect is suppressed in *aak-2(ok524)* mutants ([Figure 1c,d](#fig1){ref-type="fig"}). In addition, while null mutation of *raga-1* extends lifespan by 30% in an otherwise wild type background, it has no effect in *aak-2(ok524)* mutants ([Figure 1e](#fig1){ref-type="fig"}). Supporting the hypothesis that phosphorylation of AMPK at T172 is critical for extension of lifespan by TORC1 suppression, the extended lifespan of *raga-1* mutants was also suppressed by AAK-2 T243A ([Figure 1f](#fig1){ref-type="fig"}). These results are unlikely due to the general sickness of the *aak-2* mutants, since their lifespan can be extended by other interventions, such as dietary restriction in liquid culture or intermittent fasting ([@bib22]; [@bib27]; [@bib39]). LKB1 is the primary kinase that phosphorylates AMPK under energy stress ([@bib57]). We tested the requirement for PAR-4, the LKB1 homolog in *C. elegans,* for *raga-1* mediated longevity using animals bearing a temperature sensitive allele *par-4(it57)* ([@bib43]). *par-4(it57)* animals are refractory to the lifespan extension of *raga-1* RNAi when housed at restrictive temperatures, suggesting AMPK T172 phosphorylation by LKB1 is required for TORC1-mediated longevity ([Figure 1g](#fig1){ref-type="fig"}).

S6K has been suggested to phosphorylate AMPK alpha 2 at serine 485, resulting in inhibition of AMPK activity ([@bib14]). We examined whether phosphorylation status at the *C. elegans* equivalent of AMPK alpha 2 serine 485 mediates lifespan extension by TORC1 pathway suppression. Although we found that this serine residue is conserved in *C. elegans* (serine 551 residue in AAK-2) ([Figure 1---figure supplement 1d](#fig1s1){ref-type="fig"}) and inhibits AMPK ([Figure 1---figure supplement 1e,f](#fig1s1){ref-type="fig"}), mutating S551 to alanine does not alter the longevity response to reduced TORC1 signaling ([Figure 1---figure supplement 1g](#fig1s1){ref-type="fig"}), suggesting that this phosphorylation event is not required for TORC1-mediated longevity. Taken together, these data suggest that in *C. elegans,* AMPK is activated and critically required for lifespan extension when TORC1 is inhibited.

TORC1 and AMPK act via separable downstream mechanisms {#s2-2}
------------------------------------------------------

If AMPK acts as the key downstream effector of TORC1 mediated longevity, we reasoned that interventions that inhibit lifespan extension via AMPK activation might also block longevity resulting from suppression of TORC1. Previously, we have shown that phosphorylation of CREB-regulated transcriptional coactivator (CRTC)−1 in neurons is required for lifespan extension by constitutively activated AMPK ([@bib11]). To determine if lifespan extension via *raga-1* deletion acts via a similar mechanism, we crossed a transgene that expresses a non-phosphorylatable variant of CRTC-1^(S76A,\ S179A)^ only in neurons into *raga-1(ok386)* mutants. Although neuronal CRTC-1^(S76A,\ S179A)^ fully suppresses AMPK mediated longevity ([@bib11]), it does not similarly suppress *raga-1* mutant longevity ([Figure 1h](#fig1){ref-type="fig"}). Together these data suggest that, while AMPK is required for TORC1 mediated longevity, the mechanisms by which TORC1 suppression and AMPK activation promote healthy aging are likely separable.

Neuronal AMPK is required for TORC1-mediated longevity {#s2-3}
------------------------------------------------------

To further explore why AMPK activity is required for lifespan extension by TORC1 suppression, we asked where AMPK acts to mediate this effect. We rescued *aak-2(ok524)* mutants in specific tissues with a truncated and constitutively active form of AAK-2^aa1-321^ ([@bib40]). Ubiquitous expression of AAK-2^aa1-321^ fully restored the responsiveness of *aak-2(ok524)* mutant animals to the lifespan promoting effects of *raga-1* RNAi ([Figure 1i](#fig1){ref-type="fig"}), whereas expression of AAK-2^aa1-321^ specifically in either the intestine or muscle did not ([Figure 1j,k](#fig1){ref-type="fig"}). Remarkably, however, expressing AAK-2^aa1-321^ solely in neurons fully restored lifespan extension by *raga-1* RNAi ([Figure 1l](#fig1){ref-type="fig"}). We saw similar rescue using neuronal expression of full-length wild type *aak-2* ([Figure 1---figure supplement 1h](#fig1s1){ref-type="fig"}). These data demonstrate that activity of AMPK specifically in neurons is a critical mediator of TORC1 longevity, and also suggest that neuronal TORC1 activity itself may impact healthy aging.

TORC1 acts in neurons to regulate aging {#s2-4}
---------------------------------------

Homozygous null mutations for many TORC1 components and regulators lead to developmental arrest ([@bib2]; [@bib56]; [@bib36]) and therefore do not facilitate longevity assays. However, null mutants for *raga-1* or *rsks-1* are viable and long-lived ([@bib51]; [@bib52]). To directly examine the role of neuronal TORC1 activity on organismal aging, we rescued TORC1 pathway activity in *raga-1* and *rsks-1* mutants specifically in neurons, via ectopic expression regulated by the pan-neuronal *rab-3* promoter. These animals therefore have reduced TORC1 signaling in all tissues except neurons. Strikingly, we found that expression of *raga-1* in neurons fully suppressed the long lifespan of *raga-1* mutant animals without affecting wild type lifespan ([Figure 2a](#fig2){ref-type="fig"}). Neuronal *raga-1* fully suppressed the long lifespan both with and without the use of FUDR, a chemical inhibitor of DNA synthesis commonly used in *C. elegans* lifespan experiments to stop the production of progeny that can also lead to complex interactions with various genes and treatments in the regulation of lifespan ([@bib3]) ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). Similarly, neuronal *rsks-1* expression rescued the lifespan extension of *rsks-1* deletion mutants ([Figure 2b](#fig2){ref-type="fig"}), suggesting that neuronal regulation of longevity is not specific to RAGA-1 and extends to other TORC1 pathway components.

![TORC1 signaling is required in neurons to regulate lifespan.\
(**a**) The *raga-1(ok386)* deletion increases lifespan (p\<0.0001). However, when *raga-1* is expressed in the nervous system via extrachromosomal array using the *rab-3* promoter, *raga-1(ok386)* does not extend lifespan (p=0.7932). n = 6 independent biological replicates; sample size ranges between 77--192 deaths per treatment each replicate. *P* values are calculated with Log-rank (Mantel-Cox) test. Details on strains and lifespan replicates can be found in [Supplementary file 6](#supp6){ref-type="supplementary-material"}. (**b**) The *rsks-1(ok1255)* deletion increases lifespan (p\<0.0001). However, when *rsks-1* is expressed in the nervous system by extrachromosomal array using the *rab-3* promoter, *rsks-1(ok1255)* does not extend lifespan (p=0.6539). n = 4 independent biological replicates; sample size ranges between 81--121 deaths per treatment each replicate. *P* values are calculated with Log-rank (Mantel-Cox) test. Details on strains and lifespan replicates can be found in [Supplementary file 6](#supp6){ref-type="supplementary-material"}. (**c**) The lifespan extension resulting from *raga-1(ok386)* deletion is significantly suppressed by reintroduction of *raga-1* in the nervous system as a single copy transgene (p\<0.0001). n = 3 independent biological replicates. *P* value calculated with Log-rank (Mantel-Cox) test. As described in Materials and methods, 'neuronal *raga-1*' refers to single copy transgene driven by the *rab-3* promoter. 'somatic *raga-1'* refers to single copy transgene driven by the *eft-3* promoter. Details on strains used and lifespan replicates can be found in [Supplementary file 6](#supp6){ref-type="supplementary-material"}. (**d**) Relative *raga-1* expression generated from integrated single copy transgenes (left) compared to extrachromosomal array (right) as determined by qPCR. Points plotted are from independent biological samples. Error bars denote mean + /- SEM. *P* values determined by 2-tailed t test. *raga-1* expression driven from single copy insertion transgenes (SCIs) and controls shown on the left were replotted next to expression generated by extrachromosomal array on the right to highlight relative differences in expression. All samples were run in parallel. (**e**) *raga-1(ok386)* allele extends lifespan both in the wild type background (p\<0.0001) and with *raga-1* expressed in the intestine by extrachromosomal array using the intestine-specific *ges-1* promoter (p\<0.0001). n = 3 independent biological replicates; sample size ranges between 83--126 deaths per treatment each replicate. *P* values are calculated with Log-rank (Mantel-Cox) test. Details on strains and lifespan replicates can be found in [Supplementary file 6](#supp6){ref-type="supplementary-material"}. (**f**) Somatic (top), but not neuronal (bottom), expression of *raga-1* driven by single copy transgene rescues the small body size exhibited by *raga-1(ok386)* mutants. Scale bar = 200 μm.\
10.7554/eLife.49158.011Figure 2---source data 1.[Figure 2e](#fig2){ref-type="fig"} qPCR of raga-1 expression in SCIs and extrachromosomal lines.](elife-49158-fig2){#fig2}

Since many neuronal-specific promoters show leakiness in the intestine, especially in adult *C. elegans*, we used an RNAi protocol to eliminate transgene expression in the intestine while leaving neuronal expression intact ([Figure 2---figure supplement 2a](#fig2s2){ref-type="fig"}). Critically, in animals in which intestinal leakiness of the promoter was removed via *raga-1* RNAi, *rab-3p::raga-1* still fully suppressed *raga-1* mutant lifespan ([Figure 2---figure supplement 2b](#fig2s2){ref-type="fig"}). Additionally, we generated single copy knock-ins of *raga-1* cDNA using the SKI LODGE system ([@bib53]). We used CRISPR to insert *raga-1* cDNA sequences into an intergenic cassette which uses both the *rab-3* promoter and *rab-3* 3' UTR sequences to drive gene expression more specifically in the nervous system ([@bib53]). We also knocked *raga-1* cDNA into a cassette that uses the *eft-3* promoter to express *raga-1* across all somatic tissues. Remarkably, *raga-1* expressed in the nervous system by single copy transgene effectively rescued *raga-1* lifespan, despite its more restricted and lower level of expression ([Figure 2c,d](#fig2){ref-type="fig"}). In contrast, expressing *raga-1* directly in the intestine by multicopy array using the intestine-specific *ges-1* promoter did not suppress *raga-1* mutant longevity ([Figure 2e](#fig2){ref-type="fig"}). Expression of *raga-1* in the nervous system by single copy transgene did not rescue other phenotypes resulting from loss of RAGA-1 function, including reduced body size ([Figure 2f](#fig2){ref-type="fig"}) and developmental delay ([Figure 2---figure supplement 3](#fig2s3){ref-type="fig"}). Together, these results show that TORC1 activity specifically in neurons modulates systemic aging, and this activity can be uncoupled from its regulation of growth and development.

Neuronal RAGA-1 modulates aging via neuropeptide signaling {#s2-5}
----------------------------------------------------------

To identify mechanisms specifically coupled to neuronal RAGA-1 regulation of lifespan, we examined the transcriptomes of wild type ('WT'), *raga-1* mutant ('mutant') and *raga-1* mutant with extrachromosomal neuronal *raga-1* expression ('rescue') *C. elegans* by RNA-Seq ([Supplementary files 1](#supp1){ref-type="supplementary-material"}--[3](#supp3){ref-type="supplementary-material"}). We performed a cluster analysis that takes into account trends in gene expression across all three conditions to identify genes that change in the *raga-1* mutant and are reversed by neuronal rescue. As expected given the specific nature of neuronal *raga-1* rescue of lifespan but not other *raga-1* phenotypes, the majority of differentially expressed genes changed similarly in the *raga-1* mutant and in the rescue line ([Figure 3---figure supplement 1a](#fig3s1){ref-type="fig"}). However, a small number of genes that showed increased or decreased expression in the *raga-1* mutant were rescued by the neuronal *raga-1* array ([Figure 3a](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1a](#fig3s1){ref-type="fig"}). Interestingly, functional analysis of the genes within these clusters reveals an enrichment for Gene Ontology (GO) terms related to organelle organization, organelle fission, and unfolded protein/ER stress pathways that are upregulated in the *raga-1* mutant but not in rescue, whereas GO terms related to neuronal function, including synaptic structure and signaling as well as regulation of dauer entry are enriched in the cluster of genes that show reduced expression in *raga-1* but not in rescue ([Figure 3b](#fig3){ref-type="fig"}). These GO terms are also revealed in pairwise comparisons designed to identify biological processes that differ between wild type and *raga-1*, but not between wild type and neuronal rescued animals ([Figure 3---figure supplement 1b,c](#fig3s1){ref-type="fig"}).

![Neuronal TORC1 modulates aging via changes to organelle organization and neuropeptide signaling.\
(**a**) Cluster analysis identified 59 genes that show increased expression in *raga-1(ok386)* that is reversed by neuronal rescue array (Cluster 3, top) and 107 genes that show decreased expression in *raga-1* that is reversed by neuronal rescue (Cluster 4, bottom). (**b**) Over-representation analysis of the Gene Ontology biological process terms for genes comprising each of the clusters shown in panel (**a**). (**c, d**) qPCR to validate increased expression of *daf-28* (**c**) and *ins-6* (**d**) in independent samples. Samples were generated from L4 larvae to match the timepoint of RNA-Seq sample collection. Independent biological replicates were processed and amplified in parallel. 'Ex\[neuronal rescue\]' refers to *raga-1(ok386)* animals rescued by extrachromosomal array, 'SCIs\[neuronal rescue\]' refers to *raga-1(ok386)* animals rescued by single copy insertion. *P* values determined by 2-tailed t test. Source data are provided in [Figure 3---source data 1](#fig3sdata1){ref-type="supplementary-material"}. (**e**) The *unc-64(e246)* hypomorphic allele significantly extends lifespan in *raga-1* neuronal rescue background (p\<0.0001), but not in wild type (p=0.3449) or *raga-1* mutant (p=0.2708). n = 3 independent biological replicates, sample size ranges between 64--121 deaths per treatment each replicate. *P* values are calculated with Log-rank (Mantel-Cox) test. Details on strains and lifespan replicates can be found in [Supplementary file 6](#supp6){ref-type="supplementary-material"}.\
10.7554/eLife.49158.017Figure 3---source data 1.[Figure 3c and d](#fig3){ref-type="fig"} qPCR of daf-28 and ins-6.](elife-49158-fig3){#fig3}

Among the genes represented in Cluster 4 (decreased in *raga-1*, increased in rescue) are multiple insulin-like peptide genes (*daf-28*, *ins-6*, *ins-26*, *ins-30*) including two, *daf-28* and *ins-6*, that when overexpressed are sufficient to suppress the lifespan extension resulting from loss of chemosensory function ([@bib6]) ([Supplementary file 2](#supp2){ref-type="supplementary-material"}). We verified increased expression of *daf-28* and *ins-6*, as well as other identified changes in gene expression, in L4 animals rescued either by extrachromosomal array or by single copy transgene knock-in by qPCR ([Figure 3c,d](#fig3){ref-type="fig"}, [Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}). In adults, the levels of *ins-6* expression induced by neuronal or somatic expression of *raga-1* are indistinguishable, suggesting its regulation is entirely neuronal ([Figure 3---figure supplement 3](#fig3s3){ref-type="fig"}). These data suggest that neuronal TORC1 might mediate systemic longevity cell nonautonomously via secretion of insulin-like peptides or other *raga-1* dependent neuronal signals.

Neuropeptides are released from dense core vesicles (DCVs) ([@bib35]). If neuronal RAGA-1 suppresses *raga-1* longevity via expression of insulin-like peptides or other neuropeptide signals, we reasoned the lifespan of *raga-1* neuronal rescue worms might be de-repressed by blocking neuropeptide release. We utilized mutants for *unc-64*, a homolog of mammalian syntaxin, an essential plasma membrane receptor for DCV exocytosis to test whether impairing neuronal function in this way would block the ability of the neuronal extrachromosomal *raga-1* array to rescue. Hypomorphic *unc-64(e246)* mutant animals are defective for dense core vesicle docking ([@bib65]) and remarkably completely remove suppression of *raga-1* lifespan by neuronal RAGA-1. *raga-1; unc-64* double mutant animals with the neuronal rescue array live more than 40% longer than *raga-1* neuronal rescue animals ([Figure 3e](#fig3){ref-type="fig"}). The longevity effects by *unc-64* mutation on *raga-1* neuronal rescue animals, combined with the RNA seq results, strongly suggest that neuronal TORC1 actively causes the release of neuropeptide signals to limit longevity cell nonautonomously.

Neuronal RAGA-1 drives peripheral mitochondrial fragmentation in aging animals {#s2-6}
------------------------------------------------------------------------------

Since genes linked to organelle organization were upregulated in the *raga-1* mutant but not in rescue, we explored whether this might be causal to longevity of the *raga-1* mutants.

Mitochondria can dynamically move between fused and fragmented networks in response to changes in the cellular environment, mediated in *C. elegans* by the GTPases: FZO-1 (fusion) and DRP-1 (fission) ([@bib60]). We examined mitochondrial networks in young and old *C. elegans* in multiple tissues using reporters expressing GFP fused with a fragment from the mitochondrial outer membrane protein TOMM-20, which includes a transmembrane domain that anchors the fusion protein to mitochondria ([@bib61]). For neurons and muscle, we developed an ImageJ/FIJI macro, 'MitoMAPR', to characterize and quantify changes in mitochondrial architecture and morphology in *C. elegans* cells. MitoMAPR uses several pre-existing image enhancement filters to augment the signal clarity of images, converting the mitochondrial signals into skeleton-like binary backbones ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}), and quantifying various attributes of the mitochondrial network as described in ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}). Coupled with a high-throughput batch processing mode, this macro allows us to characterize changes in mitochondrial object length, distribution, network coverage and complexity in a large number of images acquired from the samples in question ([Figure 4](#fig4){ref-type="fig"}, [Figure 4---figure supplement 3](#fig4s3){ref-type="fig"}, [Figure 4---figure supplement 5](#fig4s5){ref-type="fig"}). Age induces fragmentation of mitochondria in neurons, intestine, and muscle, in wild type animals but degeneration is not seen in long lived *raga-1* mutants ([Figure 4](#fig4){ref-type="fig"}, [Figure 4---figure supplement 3](#fig4s3){ref-type="fig"}, [Figure 4---figure supplement 4](#fig4s4){ref-type="fig"}, [Figure 4---figure supplement 5](#fig4s5){ref-type="fig"}).

![Neuronal RAGA-1 drives mitochondrial fragmentation in muscle cells.\
(**a**) Representative pictures showing that loss of *raga-1* preserves muscle mitochondrial content during aging, while neuronal RAGA-1 reverses these effects as seen in the corresponding skeletonized images (Left) post MitoMAPR processing. The mitochondrial skeleton (red) is overlaid on binary images. TOMM-20^aa1-49^::GFP reporter labels mitochondria in young (day 2) and old (day 11) wild type, *raga-1(ok386)* mutant and *raga-1* neuronal rescue animals (n = 2 independent trials, 16--29 cells were imaged per genotype each time point per replicate). Scale bar represents 25 μm. (**b**) zoomed insets from (**a**) (yellow boxes). (**c--h**) Quantification showing that neuronal *raga-1* rescue animals also have decreased mitochondrial coverage (**c**), greater degree of fragmentation as seen by decreased mitochondrial length (**d**) and area (**e**) and increased object number normalized to area (**f**) compared to *raga-1* mutants. Data are represented as mean ±S.D. P value: NS no significance, \*\<0.05, \*\*\<0.01, \*\*\*\<0.001, between comparisons as indicated by bars. Statistical significance was determined by One-way ANOVA and Welch's t test. 16--29 cells were quantified per genotype for each time point per replicate (n = 2 independent trials, 25--30 cells were imaged per genotype each time point per replicate). Source data are provided in [Figure 4---source data 1](#fig4sdata1){ref-type="supplementary-material"}.\
10.7554/eLife.49158.027Figure 4---source data 1.[Figure 4c-h](#fig4){ref-type="fig"} and [Figure 4---figure supplement 5](#fig4s5){ref-type="fig"} Effects of neuronal *raga-1* rescue on parameters of muscle mitochondrial morphology.](elife-49158-fig4){#fig4}

To test whether mitochondria in peripheral tissues might be affected by signals generated by neuronal TORC1 activity cell nonautonomously, we examined mitochondrial morphology in body wall muscle in wild type, *raga-1* mutant and *raga-1* neuronal rescue animals ([Figure 4a,b](#fig4){ref-type="fig"}). Mitochondrial networks in wild type muscle cells showed decreased total coverage (measured by percentage of cell area covered by mitochondria) ([Figure 4c](#fig4){ref-type="fig"}) and size (measured by length and area of each mitochondria particle) with age ([Figure 4d,e](#fig4){ref-type="fig"}). Further suggesting an increase in fragmentation of mitochondria in WT muscle cells with age as seen previously ([@bib61]), we saw an increased object number normalized to area ([Figure 4f](#fig4){ref-type="fig"}). Strikingly, loss of *raga-1* attenuates both the age-related decline in mitochondrial coverage and the increase in fragmentation ([Figure 4c,d,e,f](#fig4){ref-type="fig"}). Interestingly, the mitochondrial architecture in *raga-1* mutants contains fewer networks and junction points compared to WT at all ages tested, suggesting that mitochondria are longer but less interconnected ([Figure 4---figure supplement 5](#fig4s5){ref-type="fig"}). Next, we examined the impact of neuronal *raga-1* on mitochondria in muscle cells. *raga-1* neuronal rescue suppressed the effect of *raga-1* deletion on muscle mitochondria in both young and old animals, causing reduced coverage, decreased size and a higher degree of fragmentation ([Figure 4c,d,e,f](#fig4){ref-type="fig"}). Further, network counts in *raga-1* neuronal rescue animals are not significantly different to wild type in young or old animals ([Figure 4---figure supplement 5](#fig4s5){ref-type="fig"}). Together, these data suggest that loss of *raga-1* specifically in neurons can maintain youthful mitochondrial network states with age in non-neuronal tissues.

Next, we examined the effect of loss of UNC-64/syntaxin function, which de-represses the effects of neuronal TORC1 on longevity, on muscle mitochondria ([Figure 4---figure supplement 6a,b](#fig4s6){ref-type="fig"}). In young *unc-64* mutants, mitochondria coverage and area were decreased in muscle cells and the networks show a higher degree of fragmentation compared to wild type. However, in *unc-64* mutants, unlike for WT, neither mitochondrial coverage nor area show significant alterations with age ([Figure 4---figure supplement 6c,d,e,f](#fig4s6){ref-type="fig"}). Taken together, our data suggest that neuronal signaling driven by TORC1 can cell nonautonomously drive mitochondrial fragmentation in peripheral tissues.

*raga-1* deletion specifically requires a fused mitochondrial network to promote longevity {#s2-7}
------------------------------------------------------------------------------------------

We sought to determine whether the changes we observed in mitochondrial network state were causally associated with *raga-1* longevity. First, we asked whether *raga-1* mutant animals require a fused mitochondrial network to extend lifespan. We crossed the *raga-1(ok386)* mutants with animals carrying a null allele of *fzo-1*, which encodes a protein orthologous to mammalian mitofusins. *fzo-1(tm1133)* mutant animals are therefore defective in mitochondrial fusion and consequently have fragmented mitochondria ([@bib8]; [@bib29]). *fzo-1(tm1133)* significantly suppresses the lifespan extension seen in *raga-1* mutants, which suggests that mitochondrial fusion is required for *raga-1* mediated longevity ([Figure 5a](#fig5){ref-type="fig"}). Mutations in *fzo-1* suppress the long lifespan both with and without the use of FUDR ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). Deleting the *C. elegans* dynamin-related protein 1 (DRP-1), which is required for mitochondrial fission, does not block *raga-1(ok386)* longevity ([Figure 5b](#fig5){ref-type="fig"}), indicating that *raga-1* longevity specifically requires mitochondria fusion. In addition to the previous data on the effects of neuronal CRTC-1, these data emphasize how AMPK and TORC1 modulate aging in *C. elegans* by distinct mechanisms: AMPK longevity requires both fusion and fission ([@bib61]), while lifespan extension by in *raga-1* mutants specifically requires mitochondrial fusion.

![*raga-1* deletion requires a fused mitochondrial network to promote longevity.\
(**a**) *fzo-1(tm1133) raga-1(ok386)* double mutants, which are deficient in mitochondrial fusion, have significantly shortened lifespan compared to *raga-1(ok386)* single mutants (p\<0.0001). However, *raga-1(ok386); drp-1(tm1108)* double mutants, which are deficient in mitochondrial fission, have similar lifespan compared to *raga-1(ok386)* single mutants (p=0.1420) (**b**). n = 4 independent biological replicates; sample size ranges between 71--128 deaths per treatment each replicate. Lifespan curves in a and b were generated in the same experiment but plotted separately for clarity, therefore wild type and *raga-1* control curves are shared by both. *P* values were calculated with Log-rank (Mantel-Cox) test. Details on strains and lifespan replicates can be found in [Supplementary file 6](#supp6){ref-type="supplementary-material"}. (**c**) When *fzo-1* is rescued in the *fzo-1(tm1133)* loss-of-function mutants using the neuronal-specific *rab-3* promoter, the lifespan extension by *raga-1* deletion is not fully restored (p=0.0428). n = 3 independent biological replicates; sample size ranges between 71--101 deaths per treatment each replicate. *P* values were calculated with Log-rank (Mantel-Cox) test. Details on strains and lifespan replicates can be found in [Supplementary file 6](#supp6){ref-type="supplementary-material"}. (**d**) When *fzo-1* is rescued in the *fzo-1(tm1133)* loss-of-function mutants using the muscle-specific *myo-3* promoter, the lifespan extension by *raga-1* deletion is not restored (p=0.2011). n = 3 independent biological replicates; sample size ranges between 77--95 deaths per treatment each replicate. *P* values were calculated with Log-rank (Mantel-Cox) test. Details on strains and lifespan replicates can be found in [Supplementary file 6](#supp6){ref-type="supplementary-material"}. (**e**) When *fzo-1* is rescued in the *fzo-1(tm1133)* loss-of-function mutants using the intestinal-specific *ges-1* promoter, the lifespan extension by *raga-1* deletion is fully restored (p\<0.0001). n = 3 independent biological replicates; sample size ranges between 43--104 deaths per treatment each replicate. *P* values were calculated with Log-rank (Mantel-Cox) test. Details on strains and lifespan replicates can be found in [Supplementary file 6](#supp6){ref-type="supplementary-material"}. (**f**) The *drp-1(tm1108)* deletion allele significantly extends lifespan in *raga-1* neuronal rescue background (p\<0.0001), but not in wild type (p=0.3440) or *raga-1* mutant animals (p=0.4934). n = 4 independent biological replicates; sample size ranges between 78--120 deaths per treatment each replicate. *P* values are calculated with Log-rank (Mantel-Cox) test. Details on strains and lifespan replicates can be found in [Supplementary file 6](#supp6){ref-type="supplementary-material"}.](elife-49158-fig5){#fig5}

We examined which tissues require fused mitochondrial networks to facilitate lifespan extension via *raga-1* deletion. We restored mitochondrial fusion specifically in neurons in *fzo-1(tm1133)* mutants via rescue of *fzo-1* cDNA with a pan-neuronal *rab-3* promoter. This neuronal rescue failed to restore lifespan extension by loss of *raga-1* ([Figure 5c](#fig5){ref-type="fig"}). Similarly, expression of *fzo-1* in muscles failed to restore lifespan extension ([Figure 5d](#fig5){ref-type="fig"}), suggesting that mitochondrial fusion in neither neurons nor muscle underpin lifespan extension by TORC1 suppression. In contrast however, restoring mitochondrial fusion in intestine by expressing *fzo-1* in the *fzo-1(tm1133)* mutants enabled *raga-1* deletion to significantly extend lifespan ([Figure 5e](#fig5){ref-type="fig"}). These data support the hypothesis that neuronal RAGA-1 activity modulates lifespan via cell nonautonomous regulation of mitochondrial dynamics in distal tissues.

Neuronal RAGA-1 suppresses lifespan cell nonautonomously via mitochondrial fission {#s2-8}
----------------------------------------------------------------------------------

Finally, having shown that mitochondrial fusion is required for lifespan extension in *raga-1(ok386)* mutants, we tested whether neuronal rescue of *raga-1* suppresses lifespan via promoting peripheral mitochondrial fragmentation. We generated animals carrying three perturbations: null mutation in *raga-1,* rescue of *raga-1* in neurons, and null mutation of *drp-1*, which we reasoned would block the ability of neuronal TORC1 to induce mitochondrial fragmentation in peripheral tissues. Notably, driving mitochondrial fusion by *drp-1* fully restores longevity in neuronal *raga-1* rescue animals to that of single *raga-1* mutants ([Figure 5f](#fig5){ref-type="fig"}). These data suggest that indeed, neuronal TORC1 modulates lifespan via cell nonautonomous effects on mitochondrial dynamics. In summary, our results highlight a critical role of neuronal TORC1 activity on healthy aging, and suggest that lifespan extension by reduced TORC1 signaling requires a fused mitochondrial network which itself can be modulated via TORC1 activity in neurons.

Discussion {#s3}
==========

Taken together, our data suggest that AMPK and TORC1 can coordinate in neurons to modulate systemic organismal aging cell nonautonomously. Although primarily AMPK is regarded as an upstream suppressor of TORC1, our data suggest that for aging, lifespan extension via suppression of TORC1 activates and requires functional AMPK in neurons. However, lifespan extension by TORC1 suppression and AMPK activation in *C elegans* differ in two key aspects. First, expression of CRTC-1^S76A,\ S179A^ in neurons completely suppresses AMPK longevity but has little effect on *raga-1* mutant lifespan. Second, whereas AMPK longevity requires both mitochondrial fusion and fission mechanisms to be functional ([@bib61]), lifespan extension by *raga-1* deletion only requires mitochondrial fusion. Therefore, although both AMPK and TORC1 can modulate longevity and mitochondria dynamics cell nonautonomously in *C. elegans*, both the origin of those neuronal signals and the functional role mitochondria play in responding to them appear to differ.

Many of the described experiments used FUDR, a chemical inhibitor of thymidine synthesis, to block the production of progeny. While the actions of FUDR in postmitotic adult *C. elegans* are thought to act primarily in the germline to inhibit DNA replication in the dividing germ cells, there is also evidence that FUDR can act in somatic tissue and can lead to complex interactions with various genes and treatments in the regulation of lifespan ([@bib3]). As such, we chose a relatively small dose (40 μM) to use for our experiments, and importantly, verified key findings in lifespan experiments that did not use FUDR.

Beyond requiring LKB1/PAR-4, how TORC1 suppression activates AMPK in *C. elegans* remains unclear. S6K inhibits AMPK in mouse hypothalamus via S485 (or 491 depending on the isoform) ([@bib14]). Although our data suggest the conserved serine 551 residue is an inhibitory phosphorylation site in *C. elegans*, phosphorylation of AAK-2 S551 is not required for TORC1 mediated longevity. Several additional mechanisms have been recently identified that modulate AMPK activity, including an increasing number of post-translational modifications of the α subunit, expression levels of γ subunits and recruitment of LKB1 to lysosomal surface by the scaffold protein AXIN ([@bib25]; [@bib58]; [@bib64]). It remains to be tested whether these mechanisms are utilized by TORC1 to modulate AMPK in neurons, and whether they are relevant in the context of aging. Interestingly, *rsks-1* mutants require the creatine kinase, ARGK-1, which is primarily expressed in glial cells, to activate AMPK ([@bib42]). S6K1 has also been shown to inhibit AMPK in the hypothalamus in mice ([@bib14]). Together these data support a hypothesis that AMPK mediates TORC1 longevity in neurons.

While AMPK has been shown to act in neurons to promote longevity ([@bib11]; [@bib59]), one highlight of our study is that TORC1 itself has critical functions in neurons to modulate lifespan. It is especially striking that when TORC1 signaling is suppressed in all the major metabolically active tissues in *C. elegans* but active in neurons, animals are not long lived. *raga-1* or *rsks-1* neuronal rescued animals share non-aging related phenotypes with *raga-1* or *rsks-1* mutants, such as smaller body size, delayed development and reduced brood size (data not shown). These results suggest that neuronal TORC1 might modulate lifespan through a specific mechanism that is uncoupled from the broad effects of TORC1 on growth and anabolism, for example via its regulation of insulin-like or other neuropeptides that act systemically to regulate longevity. Understanding where and how RAGA-1 acts in the nervous system and whether suppressing TORC1 signaling only in neurons either genetically or pharmacologically is sufficient to promote healthy aging is now a key future goal.

Our data suggest that neuropeptide signals may act downstream of neuronal TORC1 to communicate with peripheral tissues. Indeed, we identified two insulin-like peptides, INS-6 and DAF-28, that are regulated by neuronal expression of *raga-1*. Both peptides have been shown to be regulated by food cues, and interestingly, when overexpressed are sufficient to suppress the long lifespan caused by loss of sensory signaling through the TAX-2/TAX-4 cyclic nucleotide gated channel ([@bib6]). Whether these or other neuropeptides mediate the effects of neuronal TORC1 signaling on lifespan remains to be explored. With recent findings that neuropeptides influence aging in mammals ([@bib48]), our study provides a critical starting point to investigate the identity and regulation of the neuropeptides and/or neurotransmitters that directly modulate TORC1 longevity.

Rapamycin suppresses TORC1 and alleviates a plethora of age-related pathologies and functional decline in mice, slowing age-related degenerative or neoplastic changes in liver, endometrium, heart and bone marrow ([@bib13]; [@bib17]; [@bib62]). Moreover, short term rapamycin administration has significant anti-aging effects ([@bib7]). In addition, metformin, an anti-diabetic drug which both activates AMPK and inhibits TORC1 via AMPK-dependent and -independent mechanisms ([@bib28]; [@bib31]), extends lifespan in nematodes and mice ([@bib41]; [@bib44]). The critical site of action for the anti-aging effects of rapamycin and metformin remain unknown. Our findings raise the exciting possibility that their effects on life- and healthspan could be mediated through their regulation of TORC1 and AMPK in the nervous system.

Finally, we identified mitochondria as the downstream 'receivers' of TORC1 mediated neuronal signals important to directly influence lifespan. Mitochondria are major organelles for energy and intermediate metabolite production, with critical roles in the aging process ([@bib37]). Our finding that *raga-1* mutant animals have hyperfused mitochondria is consistent with the in vitro mitochondrial hyperfusion induced by starvation or mTORC1 inhibition, which potentially allows more efficient ATP production and prevents healthy mitochondria from being degraded by mitophagy ([@bib20]). We further show that driving mitochondrial fission blocks the longevity of *raga-1* mutants, and driving fusion de-represses longevity in the presence of neuronal RAGA-1. Our results therefore unravel two critical aspects regarding the role of mitochondrial fusion in TORC1-mediated longevity: first, mitochondrial fission in peripheral tissues can be driven in a cell nonautonomous manner by neuronal RAGA-1; second, mitochondrial fusion is causally linked to *raga-1* longevity.

These and other recent work highlight how mitochondrial fission and fusion influence aging in a context-dependent manner: several longevity interventions require fusion ([@bib12]), while promoting fission can also extend lifespan in *Drosophila* ([@bib47]), and dietary restriction and AMPK mediated longevity in *C. elegans* require both fusion and fission ([@bib61]). Comparative analysis of the functional roles different mitochondrial network states play in AMPK and TORC1 longevity provide a unique opportunity to dissect out how mitochondrial networks might be modulated to promote healthy aging. Together, our data emphasize the role of TORC1 in the nervous system in modulating whole body metabolism and longevity. Further studies will help to elucidate the molecular identities of the neuronal signals and periphery receptors that underlie neuronal TORC1 activity to influence aging, and whether neuronal TORC1 might modulate aging in organisms beyond *C. elegans*.

Materials and methods {#s4}
=====================

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                Designation                           Source or reference                                             Identifiers                                                                                                           Additional\
  (species) or resource                                                                                                                                                                                                                                    information
  ---------------------------- ------------------------------------- --------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------
  Strain\                      N2                                    Caenorhabditis Genetics Center                                  WB Cat\# N2\_(ancestral), RRID:[WB-STRAIN:N2\_(ancestral)](https://scicrunch.org/resolver/WB-STRAIN:N2_(ancestral))   Laboratory reference strain
  (*Caenorhabditis elegans*)                                                                                                                                                                                                                               

  Strain (*C. elegans*)        VC222                                 Caenorhabditis Genetics Center                                  WB Cat\# VC222, RRID:[WB-STRAIN:VC222](https://scicrunch.org/resolver/WB-STRAIN:VC222)                                Genotype:*raga-1(ok386) II.*

  Strain\                      RB754                                 Caenorhabditis Genetics Center                                  WB Cat\# RB754, RRID:[WB-STRAIN:RB754](https://scicrunch.org/resolver/WB-STRAIN:RB754)                                Genotype: *aak-2(ok524) X.*
  (*C. elegans*)                                                                                                                                                                                                                                           

  Strain (*C. elegans*)        WBM997                                This study                                                                                                                                                                            Genotype: *aak-2(wbm20) X.*

  Strain\                      RB1206                                Caenorhabditis Genetics Center                                  WB Cat\# RB1206, RRID:[WB-STRAIN:RB1206](https://scicrunch.org/resolver/WB-STRAIN:RB1206)                             Genotype: *rsks-1(ok1255) III.*
  (*C. elegans*)                                                                                                                                                                                                                                           

  Strain (*C. elegans*)        WBM536                                This study                                                                                                                                                                            Genotype: *wbmEx238\[rab-3p::raga-1 cDNA::SL2::mCherry::unc-54 3\'UTR\]*

  Strain (*C. elegans*)        WBM772                                This study                                                                                                                                                                            Genotype: *wbmEx333 \[rab-3p::rsks-1 cDNA::SL2::mCherry::unc-54 3\'UTR\]*

  Strain (*C. elegans*)        WBM1167                               This study                                                                                                                                                                            Genotype: *wbmIs79\[eft-3p::3XFLAG::raga-1::SL2::wrmScarlet::unc-54 3\'UTR, \*wbmIs67\]*

  Strain (*C. elegans*)        WBM1168                               This study                                                                                                                                                                            Genotype: *wbmIs80\[rab-3p::3XFLAG::raga-1::SL2::wrmScarlet::rab-3 3\'UTR, \*wbmIs68\]*

  Strain\                      WBM650                                This study                                                                                                                                                                            Genotype: *wbmEx271 \[ges-1p::raga-1 cDNA::SL2::mCherry::unc-54 3\'UTR; rol-6 (su1006)\]*
  (*C. elegans*)                                                                                                                                                                                                                                           

  Strain (*C. elegans*)        WBM671                                PMID:[29107506](https://www.ncbi.nlm.nih.gov/pubmed/29107506)                                                                                                                         Genotype:*wbmEx289 \[myo-3p::tomm20 aa1-49::GFP::unc54 3\'UTR\]*

  Strain (*C. elegans*)        WBM955                                This study                                                                                                                                                                            Genotype:\
                                                                                                                                                                                                                                                           *wbmEx373 \[rab-3p::tomm-20 aa1-49::GFP::unc-54 3\'UTR, rol-6\]*

  Strain (*C. elegans*)        WBM926                                PMID:[29107506](https://www.ncbi.nlm.nih.gov/pubmed/29107506)                                                                                                                         Genotype: *wbmEx367\[ges-1p::tomm20 aa1-49::GFP::unc-54 3\'UTR\]*

  Strain (*C. elegans*)        CU5991                                Caenorhabditis Genetics Center                                  WB Cat\# CU5991, RRID:[WB-STRAIN:CU5991](https://scicrunch.org/resolver/WB-STRAIN:CU5991)                             Genotype: *fzo-1 (tm1133) II.*

  Strain (*C. elegans*)        CU6372                                Caenorhabditis Genetics Center                                  WB Cat\# CU6372, RRID:[WB-STRAIN:CU6372](https://scicrunch.org/resolver/WB-STRAIN:CU6372)                             Genotype: *drp-1(tm1108) IV.*

  Strain (*C. elegans*)        WBM861                                This study                                                                                                                                                                            Genotype: *fzo-1(tm1133) II; wbmEx335 \[rab-3p:3xFLAG fzo-1 cDNA: unc54 3\'UTR, myo-3p:mCherry\]*

  Strain (*C. elegans*)        WBM612                                PMID:[29107506](https://www.ncbi.nlm.nih.gov/pubmed/29107506)                                                                                                                         Genotype: *fzo-1 (tm1133) II; wbmEx258 \[pHW11 (myo-3p::3xFLAG::fzo-1 cDNA::unc-54 3\'UTR) + pRF4 (rol-6(SU1006))\]*

  Strain\                      WBM639                                PMID:[29107506](https://www.ncbi.nlm.nih.gov/pubmed/29107506)                                                                                                                         Genotype: *fzo-1(tm1133) II; wbmEx276 \[pHW18 (ges-1p::3xFLAG::fzo-1*\
  (*C. elegans*)                                                                                                                                                                                                                                           *cDNA::unc54 3'UTR) +*\
                                                                                                                                                                                                                                                           *pRF4(rol-6(SU1006))\]*

  Antibody                     Phospho-AMPKα (Thr172) antibody       Cell Signaling Technology                                       Cat\# 2535, RRID:[AB_331250](https://scicrunch.org/resolver/AB_331250)                                                

  Antibody                     Beta actin antibody                   Abcam                                                           Cat\# ab8226, RRID:[AB_306371](https://scicrunch.org/resolver/AB_306371)                                              

  Software                     MitoMAPR                              This study                                                                                                                                                                            Source code provided as [Source code 1](#scode1){ref-type="supplementary-material"}

  Commercial\                  TruSeq Stranded mRNA LT - Set A kit   Illumina                                                        RS-122--2101                                                                                                          
  assay or kit                                                                                                                                                                                                                                             
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Worm strains {#s4-1}
------------

Worms were grown at 20°C on nematode growth media (NGM) plates seeded with *E. coli* strain OP50-1(CGC) with standard techniques ([@bib9]). Information for all strains used is in [Supplementary file 4](#supp4){ref-type="supplementary-material"}.

RNAi feeding {#s4-2}
------------

Feeding RNAi clones were obtained from the Ahringer or Vidal RNAi libraries and sequence-verified before using. To use, bacteria were grown overnight in LB broth with 100 μg/mL carbenicillin and 12.5 μg/mL tetracycline, seeded on NGM plates with 100 μg/mL carbenicillin (NG Carb) and allowed 48 hr to grow at room temperature. At least 4 hr before use, 0.1M IPTG solution with 100 μg/mL carbenicillin and 12.5 μg/mL tetracycline was added to the bacterial lawn to induce dsRNA expression.

Lifespan experiments {#s4-3}
--------------------

All worms were kept fed for at least two generations on OP50-1 bacteria. Before the start of each lifespan experiment, gravid adult worms were bleached and eggs were fed HT115 bacteria until adulthood to either start the lifespan experiment or a timed egg lay to obtain synchronized populations. Day 1 of lifespan marks the onset of egg laying. In the cases where FUDR is used, plates were seeded with bacteria, allowed 24 hr to grow and 100 μl of 1 mg/mL FUDR solution was seeded on top of the bacteria lawn for each plate containing 10 mL NGM (for a final concentration of 40 μM). FUDR was allowed 24 hr to diffuse to the whole plate before plates were used. When combining FUDR with RNAi treatments, to overcome potential inhibition of FUDR on dsRNA expression in bacteria, plates were induced with IPTG solution 18 hr after seeding; FUDR was applied 24 hr after seeding; IPTG was applied again 4 hr before use.

Western blots {#s4-4}
-------------

More than 500 day one adults were used for each sample. Worms were collected in M9 buffer with 0.01% Tween-20 and washed three times in M9. Liquids were removed after centrifugation and samples were frozen in liquid nitrogen. For worm lysis, RIPA buffer containing protease inhibitors (Sigma, MI, USA \#8340) and phosphatase inhibitors (Roche, Basel, Switzerland \#4906845001) was added to each sample at the same volume as the worm pellet. Worms were lysed via sonication (Qsonica, CT, USA Q700). Protein concentration was measured using Pierce BCA protein assay kit (Thermo Fisher Scientific, MA, USA PI23227) following manufacturer's instructions. To denature the proteins, 5X RSB was added and samples were heated to 95°C for 5 min. Samples containing 20--30 μg protein were loaded to 10% Tris-Glycine gels (Thermo Fisher Scientific \#XP00100) for SDS-PAGE. Proteins were transferred to PVDF membranes (Thermo Fisher Scientific, \#LC2005) and blocked with 5% BSA in TBST. Primary antibodies and dilutions are: phosphor-AMPK (Cell signaling, MA, USA \#2535) 1:1000; beta actin (Abcam, Cambridge, UK \#8226) 1:1000. Antibody signals were developed using ECL Western Blotting Detection Reagent (GE Healthcare, IL, USA Catalog number: 95038--560) and bands were quantified with Gel Doc system (Bio Rad) and Image Lab software (Version 4.1).

Genotyping of deletion alleles {#s4-5}
------------------------------

Worms were individually lysed in single worm lysis buffer and lysates were used as templates for PCR reactions with a combination of 2--3 primers that will produce bands of different sizes for wild type and mutant alleles. Primers and PCR conditions for each deletion allele are listed in [Supplementary file 5](#supp5){ref-type="supplementary-material"}.

Generation of transgenes {#s4-6}
------------------------

To generate transgenic animals expressing *raga-1* in neurons, *raga-1* cDNA was PCR amplified and cloned using standard techniques into a plasmid where a 3X FLAG tag was added to the N terminus and a *gpd-2* SL2 sequence with mCherry ORF was added between *raga-1* stop codon and *unc-54* 3'UTR. *rab-3* promoter was subsequently PCR amplified and inserted. To express wild type and mutated forms of *aak-2,* both 3 kb promoter region before the *aak-2* gene and the 6.7 kb coding region were amplified from N2 genomic DNA and cloned into a plasmid, where a 3X FLAG tag and *unc-54* 3'UTR were added to the C terminus. Serine-to-alanine mutation was generated using QuikChange II XL Site-directed Mutagenesis Kit (Agilent Technologies, CA, USA 200522) following manufacturer's instructions. Transgenic strains were generated via microinjection. Detailed information on strains used is in [Supplementary file 4](#supp4){ref-type="supplementary-material"}.

Generation of single copy *raga-1* transgene knock-in strains {#s4-7}
-------------------------------------------------------------

Strains WBM1167 *N2, wbmIs79\[eft-3p::3XFLAG::raga-1::SL2::wrmScarlet::unc-54 3\'UTR, \*wbmIs67\]* and WBM1168 *N2, wbmIs80\[rab-3p::3XFLAG::raga-1::SL2::wrmScarlet::rab-3 3\'UTR, \*wbmIs68\]* were generated by CRISPR according to [@bib53]. Specifically, a homology repair template (HR) containing *raga-1::SL2* sequences was amplified from plasmid pYZ30 using primers

'5' TATAAAGATCATGACATCGATTACAAGGATGACGAcGAtAAGTCTT CAAAACGAAAAGTT'

and '

5' AACGCATGAACTCCTTGATAACTGCCTCTCCCTTGCTGACC ATGATGCGTTGAAGCAGTT',

followed by a second round of amplification using '5' CCGGGATGGACTACAAAGACCATGACGGTGATTATAAAGATCATGACATCGATTACAAGG and '5' CGTGTCCGTTCATGGATCCCTCCATGTGGACCTTGAAACGCATGAACTCCTTGATA' to extend the HR arms. A CRISPR mix containing the raga-1::SL2 HR template, and a 3x flag 3' crRNA \[5' TTACAAGGATGACGATGACA 3'\] was prepared according to [@bib45]; [@bib53] and injected into strains WBM1143 and WBM1144 ([@bib53]). Resulting CRISPR edited alleles, *wbmIs79* and *wbmIs80*, were outcrossed 6 and 5 times to N2 respectively to generate strains WBM1167 and WBM1168. To introduce *wbmIs79* and *wbmIs80* single copy transgenes into a *raga-1* mutant background the strains were crossed into WBM499 (an outcrossed *raga-1(ok386)* allele) and genotyped for the presence of the transgene by the visible expression of *wrmScarlet*, and for presence of the *ok386* deletion by PCR, using primers 5' TTCAAGTCCGAAACAGTCAATTCTC and 5' GGAACTGAAGCGATCACACCGAC. *raga-1* rescue strains are WBM1169 *raga-1 (ok386) II; wbmIs79\[eft-3p::3XFLAG::raga-1::SL2::wrmScarlet::unc-54 3\'UTR, \*wbmIs67\]* and WBM1170 *raga-1 (ok386) II; wbmIs80\[rab-3p::3XFLAG::raga-1::SL2::wrmScarlet::rab-3 3\'UTR, \*wbmIs68\].*

Determination of developmental rate {#s4-8}
-----------------------------------

Strains were fed and passaged for multiple generations on NG Carb plates seeded with HT1115 bacteria. At the start of the experiment, adult hermaphrodites were allowed to lay eggs for \~2 hr, after which, 50 eggs from each strain were picked to each of 2 new plates (100 eggs total) and left to develop at 20°C for 72--73 hr. The developmental stage was scored by eye under a light microscope on the basis of larval and adult stage specific hallmarks.

Comparison of body size {#s4-9}
-----------------------

Strains were fed and passaged for multiple generations on NG Carb plates seeded with HT1115 bacteria. To synchronize animals, L4-staged larvae were picked to a new plate and aged for two days at 20°C. Day two adult animals were picked to a new plate and anaesthetized in a drop of 0.4 mg/mL tetramisole for \~15 mins. Once the animals stopped moving, they were aligned into groups according to genotype, and imaged with an Axiocam camera on a Zeiss Discovery V8 dissection microscope.

Microscopy {#s4-10}
----------

Worms of desired stage/age were anesthetized in 0.5 mg/mL tetramisole (Sigma, T1512) diluted in M9 and mounted to 2% agarose pads. For imaging of the mitochondrial TOMM-20 reporter in the muscle, images were taken using a Zeiss Imager.M2 microscope. Apotome optical sectioning was used to acquire fluorescence and one picture with best focus was chosen for each worm for quantification (as described in [@bib61]). For imaging of mitochondria in neurons and in intestine, images were taken in the Sabri Ulker imaging lab using a Yokogawa CSU-X1 spinning disk confocal system (Andor Technology, South Windsor, CT, USA) combined with a Nikon Ti-E inverted microscope (Nikon Instruments, Melville, NY, USA). Images were taken using a 100x/1.45 oil Plan Apo objective lens, Zyla cMOS (Zyla 4.2 Plus USB3) camera and 488 nm Laser for GFP. Optical slice thickness was 0.2 µm. NIS elements software was used for acquisition parameters, shutters, filter positions and focus control. For images shown of the intestine, images were taken as a z stack and each plane was then threaded together by concatenation of the stack. These concatenated stacks were then rendered into 3d by the 3d viewer function of FIJI.

*C. elegans* mitochondrial analysis using MitoMAPR {#s4-11}
--------------------------------------------------

The images were analysed using a novel macro called MitoMAPR ([Source code 1](#scode1){ref-type="supplementary-material"}) in ImageJ or FIJI ([@bib50]). Briefly, worm muscle cells and neurons were selected as ROIs, processed and filtered using the CLAHE plugin ([@bib66]) with median filter and unsharp mask to increase the local contrast and particle distinctiveness. The ROI is then converted to a binary image to generate a 2D skeleton using the Skeletonize3D plugin ([@bib34]). This skeleton image is then dissected using the AnalyzeSkeleton function ([@bib5]) in FIJI to generate Tagged and Labelled skeletons. Labelled skeletons allow the program to count distinct mitochondrial objects while the tagged skeleton provides information about junction points, branch counts and other pre-configured attributes. MitoMAPR uses the values obtained from the AnalyzeSkeleton function to quantify previously defined aspects of the mitochondrial network ([@bib33]). The workflow of the macro is illustrated in [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}. Analysis was performed in batch mode using the MitoMAPR_Batch ([Source code 1](#scode1){ref-type="supplementary-material"}, part B) while keeping all the parameters constant. While the user is required to select a region of interest (ROI) in case of images processed singly, MitoMAPR_Batch imports the saved ROIs generated while cropping the images for cells. A separate macro called CropR (Source code file 1, part C) was written to select and crop large data sets in batch mode. The cropped dataset is then used as a batch input for MitoMAPR_Batch. The codes for the macros can be found as supplementary notes.

The attributes used here to describe alterations in the mitochondrial architecture are listed in [Supplementary file 7](#supp7){ref-type="supplementary-material"}. Additionally, to determine the complexity of the mitochondrial network, we focused on the Network and Junction Point attribute. As illustrated in [Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}, greater number of junction points in individual mitochondrial networks point towards higher complexity. The output data is kept as an array in a. CSV file that lists the values of all the above-mentioned attributes.

RNA seq sample collection, RNA extraction and library preparation {#s4-12}
-----------------------------------------------------------------

Worms were bleached to HT115 bacteria carrying L4440 vector. Synchronized populations were obtained via timed egg lay. four biological replicate samples were collected for each genotype. For each sample, an independent egg lay was performed and 1000 mid-L4 stage progeny were harvested. For the *raga-1, rab-3p::raga-1::SL2::mCherry* strain, only worms carrying the transgene were picked out to a new NGM plate using a fluorescent dissecting microscope for subsequent collection. For N2 and *raga-1* mutant animals, worms were directly washed off the plates. M9 buffer with 0.01% Tween-20 were used to wash worms off the plates. Samples were centrifuged at 2,500 rpm to pellet the worms and washed three times with M9 buffer to remove bacteria. QIAzol lysis reagent (Qiagen, Venlo, Netherlands, \#79306) was added to each sample before snap-freezing in liquid nitrogen. All samples were stored in −80°C freezer until RNA extraction.

To break the worm cuticle and improve RNA yield, all samples underwent five freeze-thaw cycles. In each cycle, samples were thawed at 37 ºC and then snap-frozen in liquid nitrogen. RNA extraction was performed immediately using QIAGEN RNeasy Mini Kit (QIAGEN, \#74104) following manufacturer's instructions. RNA quality was confirmed using Agilent Bioanalyzer 2100 (Agilent Technologies). All samples passed the quality control standard of RIN \> 8.0. mRNA libraries were prepared using TruSeq Stranded mRNA LT - Set A kit (Illumina, CA, USA RS-122--2101) following manufacturer's instructions and linked to different adaptors to enable pooling. Library quality was checked using 2200 High Sensitivity D1000 Tape Station (Agilent Technologies). Libraries were pooled and sequenced with Illumina HiSeq 2500 using 50-cycle, pair-end settings.

RNA seq gene expression and functional analysis {#s4-13}
-----------------------------------------------

### Read processing and quantification {#s4-13-1}

All samples were processed using an RNA-seq pipeline implemented in the bcbio-nextgen project (<https://bcbio-nextgen.readthedocs.org/en/latest/>). Raw reads were examined for quality issues using FastQC (<http://www.bioinformatics.babraham.ac.uk/projects/fastqc/>) to ensure library generation and sequencing data were suitable for further analysis. Reads were aligned to the Ensembl94 build of the *C. elegans* genome using STAR ([@bib15]). Quality of alignments was assessed by checking for evenness of coverage, rRNA content, genomic context of alignments, complexity and other quality checks. Expression quantification was performed with Salmon ([@bib46]) to identify transcript-level abundance estimates and then collapsed down to the gene-level using the R Bioconductor package tximport ([@bib54]).

Principal components analysis (PCA) and hierarchical clustering methods validated clustering of samples from the same sample group. Differential expression was performed at the gene level using the R Bioconductor package DESeq2 ([@bib38]). Differentially expressed genes were identified using the Likelihood Ratio Test (LRT) and significant genes were obtained using an FDR threshold of 0.01. Significant genes were separated into clusters based on similar expression profiles across the defined sample groups. Gene lists for each cluster was used as input to the R Bioconductor package clusterProfiler ([@bib63]) to perform an over-representation analysis of Gene Ontology (GO) biological process terms. A secondary pairwise analysis was also performed for all pairs of sample groups using the Wald test.

Quantitative real-time PCR {#s4-14}
--------------------------

RNA was isolated from \~200 L4 staged (for validation of RNASeq in independent samples) or Day one adult (determination of *raga-1* and *ins-6* expression in adults) *C. elegans* samples using method described above. cDNA was synthesized from 30 μg of RNA with SuperScript VILO Master Mix (ThermoFisher Scientific, 11755050) following manufacturer's instructions. 5 ng cDNA was used as template for each RT-PCR reaction. 2 or three independent biological replicates were used for each genotype/condition and always run in parallel with Taqman control probe to invariant control gene Y45F10D.4 (Ce02467253_g1) ([@bib26]), for normalization on a 96 well plate. RT-PCR was performed on the StepOne Plus qPCR Machine (Life Technologies, MA, USA) using Taqman Universal Master Mix II (Life Technologies, 4440040). Taqman probes used to target each gene of interest are as follows: Ce02445578_g1 (C28A5.2), Ce02484227_g1 (F35E12.5 (*irg-5*)), Ce02421566_m1 (Y39G10AR.6 (*ugt-31*)), Ce02488119_g1 (K10G4.5), Ce02433249_g1 (ZK84.6 (*ins-6*)), Ce02489787_g1 (Y116F11B.1 (*daf-28*)) and [Ce02439068_g1](https://www.thermofisher.com/taqman-gene-expression/product/Ce02439068_g1?CID=&ICID=&subtype=) (*raga-1)*. Relative expression levels were calculated using ΔΔCt method.

Statistics and reproducibility {#s4-15}
------------------------------

Statistical methods are indicated in the figure legends. Statistical tests were performed using Graphpad Prism versions 7.0b and 8.0 for Mac. No animals or samples were excluded from the analyses. For lifespan analyses, *p* values were calculated using Log-rank (Mantel-Cox) test. Data from all lifespan experiments are included in [Supplementary file 6](#supp6){ref-type="supplementary-material"} without excluding any lifespan replicates. For qPCR, statistical significance was determined by two-tailed *t-test* unless otherwise indicated. Data are presented as mean ± s.e.m. P value: NS no significance, \*\<0.05, \*\*\<0.01, \*\*\*\<0.001, \*\*\*\*\<0.0001 relative to controls.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your work entitled \"Neuronal TORC1 modulates longevity via AMPK and cell nonautonomous regulation of mitochondrial dynamics in *C. elegans*\" for consideration by *eLife*. Your article has been reviewed by a Senior Editor, a Reviewing Editor, and three reviewers. The following individual involved in review of your submission has agreed to reveal their identity: Seung-Jae Lee (Reviewer \#2).

Our decision has been reached after consultation between the reviewers. Based on these discussions and the individual reviews below, we regret to inform you that your work will not be considered further for publication in *eLife*.

The reviewers appreciated the importance of the work, but raised some substantial concerns regarding methodology and interpretation. In particular, the use of extrachromosomal arrays and different genetic backgrounds for various experiments raises potential concerns about technical artifacts. Due to the extensive and open-ended nature of the essential revisions, I felt that it would be difficult or impossible to address these concerns within the timeframe. If you are able to address these concerns, a suitably revised manuscript could be considered again at *eLife*.

Essential revisions:

1\) Use of extrachromosomal arrays. Most experiments using transgenes were done with extrachromosomal arrays. Minimally, multiple extrachromosomal array lines should be used to verify the results. Extrachromosomal arrays are subject to random segregation between cells and rearrange the DNA fragments in ways that cause unnatural expression of the transgenes, particularly in gut cells; thus the results about gut expression of an extrachromosomal array are not really worth considering until one observes the same thing with an integrated reporter, preferably single copy at some defined, intergenic site in the genome- or a knock-in. Positive results with arrays are more believable than negative results, but both can be misleading. Also, worth considering, extrachromosomal arrays and multicopy insertions into random genomic loci can also cause lifespan-extending dye filling defects in neurons -- case and point would be the overexpression sirtuin line that lived a long time, not because of sirtuin overexpression, but because of a dye-filling defect in the neurons.

2\) Inconsistent use of a roller background in some experiments. roller genetic background with their extrachromosomal arrays. Roller animals perpetually twist and do not have the same behavior as wild-type animals. So, comparing animals that are rolling to animals that are not, using extrachromosomal arrays, is riddled with technical concerns.

3\) Use of FUDR without controlling for potential effects of the drug. FUDR inhibits DNA synthesis, including synthesis of mitochondrial DNA. FUDR also increases the lifespan of at least one mitochondrial mutant (*gas-1*). Thus, there is reason to believe that FUDR interacts with mitochondria and that is sufficient to warrant the testing of these phenomena in the absence of FUDR to ensure what they are reporting is not FUDR dependent.

4\) In Figure 4, the authors showed that mitochondrial fusion-defective *raga-1(-); fzo-1*(-) mutants did not live long, suggesting that *raga-1* mutations increase lifespan through elevating fused mitochondria. Please show the mitochondrial patterns of *rag-1(-), raga-1(-); fzo-1*(-), and *raga-1(-); drp-1*(-) mutants to strengthen their findings.

5\) In Figure 4B and C, the authors showed that intestinal *fzo-1* is required for the lifespan extension by *raga-1* mutations. However, they did not test muscles where neuronal *raga-1* rescue restored the mitochondrial dynamics of *raga-1* mutants. They need to test whether muscle-specific *fzo-1* is also required for the lifespan extension by *raga-1* mutations and test whether neuronal *raga-1* rescue restored the mitochondrial dynamics changes by *raga-1* mutations in the intestine as well.

Reviewer \#1:

The authors of this paper have done a great job writing clearly and analyzing the data to genetically investigate how neuronal *raga-1* loss (mTORC1 component) increases longevity. The results are generally interesting in terms of understanding cell nonautonomous regulation of organelles (mitochondria), and important for the field of aging.

However, my enthusiasm for the manuscript diminished when I discovered the questionable technical quality of the transgene work and use of FUDR without an FUDR-less control to show that the phenomena are not FUDR-dependent. I want this study to be published, and wish the authors great success, but as it stands, the manuscript needs additional work to be sure of the results. Alternatively, they could implement heavy, explicit, technical caveats warning readers of the uncertainties in their results. Given the confident writing style, I believe the authors would/should probably just make better transgenes and try the experiments without FUDR. In worms, they could get their strains in hand in three weeks, split them into different biological replicates and perform a few lifespan experiments in parallel, or in tight sequential fashion in a couple of months without FUDR.

Most experiments using transgenes were done with extrachromosomal arrays. Extrachromosomal arrays are randomly arranged concatemers of injected DNA that are inherited in a non-mendelian fashion. Positive results are only preliminary and, in the past, before single copy reporter gene technology was available with Mos transposon (2008) and CRISPR based (2012/2013) methods, researchers would integrate the arrays and/or examine multiple insert lines to verify their findings. Minimally, multiple extrachromosomal array lines should have been used to verify the results; we have been given no such data. Extrachromosomal arrays are subject to random segregation between cells and rearrange the DNA fragments in ways that cause unnatural expression of the transgenes, particularly in gut cells; thus the results about gut expression of an extrachromosomal array are not really worth considering until one observes the same thing with an integrated reporter, preferably single copy at some defined, intergenic site in the genome- or a knock-in. Positive results with arrays are more believable than negative results, but both can be misleading. And, in 2018, this dated technology is no longer the standard or sufficient; rather, it should be used as preliminary data. It's also worth considering that extrachromosomal arrays and multicopy insertions into random genomic loci can cause lifespan-extending dye filling defects in neurons -- case and point would be the overexpression sirtuin line that lived a long time, not because of sirtuin overexpression, but because of a dye-filling defect in the neurons. I don\'t want to see another group get burned because of poor transgene practices. I believe that this group is doing great work and has noble intent, but simply needs a bit of guidance.

Additionally, they inconsistently use a roller genetic background with their extrachromosomal arrays. Roller animals perpetually twist and do not have the same behavior as wild-type animals. So, comparing animals that are rolling to animals that are not, using extrachromosomal arrays, is riddled with technical concerns. That is a setup for a potential incorrect answer/failure.

FUDR inhibits DNA synthesis, including synthesis of mitochondrial DNA. FUDR also increases the lifespan of at least one mitochondrial mutant (*gas-1*). Thus, there is reason to believe that FUDR interacts with mitochondria and that is sufficient to warrant the testing of these phenomena in the absence of FUDR to ensure what they are reporting is not FUDR dependent.

Again, this is a well written paper, and the results may end up being correct, but there is sufficient technical concern to ask for more data before letting the authors publish something that has several potential technical artifacts that could easily be addressed with a few modern transgenes and experiments without FUDR. This is a fantastic lab that seems to be doing great things and I want to see the technical quality of their work reflect their apparent high intellectual capacity.

Reviewer \#2:

Target of rapamycin (mTOR) and AMP-activated protein kinase (AMPK) are key mediators of longevity in various species. However, how mTOR and AMPK coordinate to promote longevity remains unclear. Here, Zhang et al. suggest that activation of AMPK and inhibition of TORC1 extend lifespan via rather distinct mechanisms. They further showed that neuronal TORC1 regulates lifespan by modulating mitochondrial dynamics in other tissues through activating neuronal AMPK. This is an excellent paper that addressed mechanisms of lifespan extension by TORC1 and AMPK pathways. The experiments were generally rigorously executed and the paper is well written. My specific comments are as follows.

1\) Through the entire paper, the authors claim that AMPK and mTOR regulates lifespan through distinct mechanisms. However, most of the results explain how AMPK acted in mTOR pathways in detail; inhibition of neuronal mTOR pathway extends lifespan possibly through neuronal AMPK. In addition, the lines of supporting evidence for the distinct aging-regulatory mechanisms by CA-AAK and inhibition of mTOR pathway are indirect. Please tone down the claims.

2\) In Figure 4, the authors showed that mitochondrial fusion-defective *raga-1(-); fzo-1*(-) mutants did not live long, suggesting that *raga-1* mutations increase lifespan through elevating fused mitochondria. Please showthe mitochondrial patterns of *rag-1(-), raga-1(-); fzo-1*(-), and *raga-1(-); drp-1*(-) mutants to strengthen their findings.

3\) In Figure 4B and C, the authors showed that intestinal *fzo-1* is required for the lifespan extension by *raga-1* mutations. However, they did not test muscles where neuronal *raga-1* rescue restored the mitochondrial dynamics of *raga-1* mutants. They need to test whether muscle-specific *fzo-1* is also required for the lifespan extension by *raga-1* mutations and test whether neuronal *raga-1* rescue restored the mitochondrial dynamics changes by *raga-1* mutations in the intestine as well.

Reviewer \#3:

In this manuscript, the authors seek to 1) establish a relationship between AMPK and neuronal TORC1 activity in the context of longevity, and 2) better understand the mechanism of TORC1 inhibition slowing aging in *C. elegans*. They find that the downstream longevity pathways of AMPK and TORC1 diverge and proceed to investigate the cell nonautonomous pathway initiated by neuronal TORC1 activity. They then investigate the downstream effects of the pathway by characterizing the mitochondrial networks of wildtype and mutants with suppressed neuronal TORC1 activity before associating the differences in the mitochondrial properties with the longevity of the latter animals.

In the opinion of this reviewer, the claims made by the authors are largely substantiated, including:

1\) AMPK is required for longevity mediated by TORC1 suppression: Substantiated

2\) TORC1 and AMPK act via separable downstream mechanisms: Substantiated.

3\) Neuronal AMPK is required for TORC1-mediated longevity: Mostly substantiated.

4\) TORC1 acts in neurons to regulate aging: Substantiated.

5\) Neuronal RAGA-1 does not reverse known pro-longevity mechanisms induced by global TORC1 suppression: Substantiated.

6\) Neuronal RAGA-1 modulates aging via neuropeptide signaling: Substantiated.

7\) Neuronal RAGA-1 drives peripheral mitochondrial fragmentation in aging animals: Substantiated.

8\) *raga-1* deletion specifically requires a fused mitochondrial network to promote longevity: Substantiated.

9\) Neuronal RAGA-1 suppresses lifespan cell nonautonomously via mitochondrial fission: Substantiated.

The major question to this reviewer about this manuscript is not whether the data are substantiated but whether the advance is substantial enough for this journal. The authors establish a relationship between AMPK and TORC1 (which was already known to exist but further defined here), but don\'t really investigate it beyond cursory genetic and biochemical characterization. They then find a cell-specific role for TORC1 and suggest a signaling mechanism (neuropeptides), but do not identify any signals. Finally, they establish mitochondrial dynamics as being necessary, but offer little insight as to how fission and more importantly, fusion, might play a mechanistic role. In short, while the paper is geared towards investigating neuronal TORC1 and how it affects longevity, they don\'t really progress or analyze the relationship between the two based on their own data. It would be nice to see a couple of the \"additional mechanisms\" (mentioned in the second paragraph of the Discussion) they favor based off their work.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

Thank you for submitting your article \"Neuronal TORC1 modulates longevity via AMPK and cell nonautonomous regulation of mitochondrial dynamics in *C. elegans*\" for consideration by *eLife*. Your article has been reviewed by and Anna Akhmanova as the Senior Editor, a Reviewing Editor, and three reviewers. The following individuals involved in review of your submission have agreed to reveal their identity: Seung-Jae V Lee (Reviewer \#1); Scott F Leiser (Reviewer \#2).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

The reviewers all agreed that the authors have substantially improved the manuscript from the initial submission and that this will represent a significant contribution. There were some remaining concerns about clarity and interpretation, which I would ask the authors to addressed by modifying the text appropriately.

Please make sure genetic nomenclature is correct. Following are some examples of errors:

Figure 5A: *"raga-1, fzo-1*" should be "*fzo-1 raga-1*" without comma.

Figure 5B: "*raga-1; drp-1*" should be all italic, even the semicolon.

In some cases it is unclear which experiments were done with extrachromosomal arrays and which were done with new single copy insertions. Please ensure that this is clearly noted.

The extrachromosomal array prab-3 ex is not listed in the strain list. And the lifespan data does not say which strains were used for which experiments. Therefore, the supplements showing which strains were used seem incomplete and the other lifespan file does not detail which strain was used in which experiment. The lifespan data should say which strains were used -- not just the genotype -- and indicate if they are single copy insertions or extrachromosomal arrays.

Please provide the NA of the 100X objective used for imaging. It will be critical for anyone wanting to reproduce this. I\'m guessing it\'s 1.4, but it would be better to know.

The microscopy in Figure 4 -- the images of mitochondrial networks in intestines are of terrific quality. How are these images shown? Are they single image planes? Are they z projections? More detail here would again help people. Even though you may have it in another publication, many would appreciate a sentence or two describing the image plane used for the image cytometry in the methods.

One reviewer had significant concerns regarding the use of FUDR and the roller background in some experiments. Although these methods are still common in the field, it would perhaps be useful to address these concerns in the text, and if data are available that do not have these potential confounds those could be included as well. In particular, this reviewer noted that FUDR enhances the effects of mitochondrial double mutants (*fzo/drp*) from your prior work and wonders if the use of FUDR could be impacting outcomes in the current study.

10.7554/eLife.49158.046

Author response

> Essential revisions:
>
> 1\) Use of extrachromosomal arrays. Most experiments using transgenes were done with extrachromosomal arrays. Minimally, multiple extrachromosomal array lines should be used to verify the results. Extrachromosomal arrays are subject to random segregation between cells and rearrange the DNA fragments in ways that cause unnatural expression of the transgenes, particularly in gut cells; thus the results about gut expression of an extrachromosomal array are not really worth considering until one observes the same thing with an integrated reporter, preferably single copy at some defined, intergenic site in the genome- or a knock-in. Positive results with arrays are more believable than negative results, but both can be misleading. Also, worth considering, extrachromosomal arrays and multicopy insertions into random genomic loci can also cause lifespan-extending dye filling defects in neurons -- case and point would be the overexpression sirtuin line that lived a long time, not because of sirtuin overexpression, but because of a dye-filling defect in the neurons.
>
> We thank the reviewers for their comments and concerns here about the use of and variability of extrachromosomal arrays, and random mutagenesis integration methods. Current methods for single copy tissue specific rescue involve MosSCI insertion, which invariably requires co-insertion of a rescue marker (usually *unc-119*), which can impact neuronal signaling. Therefore, since no usable technique was available to generate the strains needed to alleviate the reviewer's concerns, we decided to build one. Since the original submission we have made from scratch and published a CRISPR based strategy -- "Single Copy Knock-in Loci for Defined Gene Expression (SKI LODGE) in *C. elegans*" (Silva-Garcia, 2019). Building this system required CRISPR insertion and validation at safe harbor loci in intergenic regions of entire promoter sequences, upstream of a landing pad crRNA target sequence. SKI LODGE strains therefore allow insertion of a cDNA of choice at a known locus under the regulation of an ectopic tissue specific promoter. We are proud of this new system, built in response to the concerns of the reviewers, and have already sent all the strains to many labs on request and the CGC. We therefore hope that this concerted effort and resource will not only allow our data and methodologies to improve now and in the future, but support the whole field. For the purposes of this revision, we then used the pan-neuronal SKI LODGE strain to validate the key point of the paper, namely the neuronal effects of RAGA-1 on longevity. The single copy SKI LODGE neuronal RAGA-1 rescue line expresses stably and only in neurons (Silva-Garcia, 2019). We compared lifespan, growth and development in *raga-1* mutants with single copy SKI LODGE generated rescue in neurons or all somatic tissue (New Figure 2). Critically and supporting the original data, single copy rescue of RAGA-1 in neurons suppressed *raga-1* mutant longevity. These lines have no roller insertion. Expression of *raga-1* in the single copy neuronal rescue was very low compared to the somatic SKI LODGE line or the previous neuronal Ex line (Figure 2E). Strikingly, although single copy neuronal RAGA-1 rescue restored WT longevity, it did not affect body size (Figure 2F) -- these data suggest that the effects of TORC1 on growth and lifespan can be uncouple via modulation in discreet tissues.
>
> 2\) Inconsistent use of a roller background in some experiments. roller genetic background with their extrachromosomal arrays. Roller animals perpetually twist and do not have the same behavior as wild-type animals. So, comparing animals that are rolling to animals that are not, using extrachromosomal arrays, is riddled with technical concerns.

We agree with the reviewer and hope the SKI LODGE system will alleviate the need for any use of Ex line with roller in the future. We have used SKI LODGE to replicate the key finding of the paper (see above). However, we believe it was beyond the scope of feasibility for us to re-do the entire body of work using SKI LODGE: the original submission was a PhD thesis performed over 6 years, much of it before CRISPR was widely available. However, in the small number of experiments that have used *rol-6* in the manuscript, the key comparison statistically is always between two roller lines. Therefore, we do not believe behavioral differences account for the effects we see.

> 3\) Use of FUDR without controlling for potential effects of the drug. FUDR inhibits DNA synthesis, including synthesis of mitochondrial DNA. FUDR also increases the lifespan of at least one mitochondrial mutant (gas^-1^). Thus, there is reason to believe that FUDR interacts with mitochondria and that is sufficient to warrant the testing of these phenomena in the absence of FUDR to ensure what they are reporting is not FUDR dependent.

We thank the reviewers for this point and have added new data replicating the effects we see of neuronal RAGA-1 suppression of longevity and *fzo-1* suppression of *raga-1* longevity without FUDR (Figure 2---figure supplement 1 and Figure 5---figure supplement 1). All lifespan experiments done during revision did not use FUDR, including those with the SKI LODGE lines.

> 4\) In Figure 4, the authors showed that mitochondrial fusion-defective raga-1(-); fzo-1(-) mutants did not live long, suggesting that raga-1 mutations increase lifespan through elevating fused mitochondria. Please show the mitochondrial patterns of rag-1(-), raga-1(-); fzo-1(-), and raga-1(-); drp-1(-) mutants to strengthen their findings.

We thank the reviewers for this point and have added new data replicating the effects we see of neuronal RAGA-1 suppression of longevity and *fzo-1* suppression of *raga-1* longevity without FUDR (Figure 2---figure supplement 1 and Figure 5---figure supplement 1). All lifespan experiments done during revision did not use FUDR, including those with the SKI LODGE lines.

> 5\) In Figure 4B and C, the authors showed that intestinal fzo-1 is required for the lifespan extension by raga-1 mutations. However, they did not test muscles where neuronal raga-1 rescue restored the mitochondrial dynamics of raga-1 mutants. They need to test whether muscle-specific fzo-1 is also required for the lifespan extension by raga-1 mutations and test whether neuronal raga-1 rescue restored the mitochondrial dynamics changes by raga-1 mutations in the intestine as well.

We thank the reviewer for this point. We have added new data showing that muscle FZO-1 is not sufficient to rescue *raga-1* mutant longevity (Figure 5D). We have also added new data showing that *raga-1* deletion maintains mitochondrial fusion with age in the intestine Figure 4---figure supplement 4).

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

> The reviewers all agreed that the authors have substantially improved the manuscript from the initial submission and that this will represent a significant contribution. There were some remaining concerns about clarity and interpretation, which I would ask the authors to addressed by modifying the text appropriately.
>
> Please make sure genetic nomenclature is correct. Following are some examples of errors:
>
> Figure 5A: "raga-1, fzo-1" should be "fzo-1 raga-1" without comma.
>
> Figure 5B: "raga-1; drp-1" should be all italic, even the semicolon.

Thank you for bringing this to our attention. We have corrected the nomenclature in Figure 5 and in the supporting files describing the strains used for each experiment and their genotypes. In those cases where the genotypes have been abbreviated for simplicity in the figure, we have directed the reader to the full genotype information provided in the Supporting files (Supplementary file 4, Supplementary file 6).

> In some cases it is unclear which experiments were done with extrachromosomal arrays and which were done with new single copy insertions. Please ensure that this is clearly noted.

Thank you, we have clarified where necessary in the text and have amended the figures to show more explicitly which experiments were done using extrachromosomal arrays and which were done by single copy knock-in. In addition, we have added a column describing the nature of the transgene used in each strain (extrachromosomal vs. integrated multi copy array vs. single copy knock in) in Supplementary file 4 and in Supplementary file 6.

> The extrachromosomal array prab-3 ex is not listed in the strain list. And the lifespan data does not say which strains were used for which experiments. Therefore, the supplements showing which strains were used seem incomplete and the other lifespan file does not detail which strain was used in which experiment. The lifespan data should say which strains were used -- not just the genotype -- and indicate if they are single copy insertions or extrachromosomal arrays.

We apologize for the insufficient strain information initially provided in the supplements. We now provide strain numbers for all strains used and note whether the transgene used in each strain is extrachromosomal, an integrated multicopy array, or present as single cope insertion.

> Please provide the NA of the 100X objective used for imaging. It will be critical for anyone wanting to reproduce this. I\'m guessing it\'s 1.4, but it would be better to know.

Thank you, the 100x objective we used was an NA of 1.45. We have noted that information in the subsection "Microscopy".

> The microscopy in Figure 4 -- the images of mitochondrial networks in intestines are of terrific quality. How are these images shown? Are they single image planes? Are they z projections? More detail here would again help people. Even though you may have it in another publication, many would appreciate a sentence or two describing the image plane used for the image cytometry in the methods.

We thank the reviewers for bringing up this question. We have included the following additional information on how we acquired and processed images of mitochondria in the intestine and in the Materials and methods section:

"For images shown of the intestine, images were taken as a z stack and each plane was then threaded together by concatenation of the stack. These concatenated stacks were then rendered into 3d by the 3d viewer function of FIJI."

> One reviewer had significant concerns regarding the use of FUDR and the roller background in some experiments. Although these methods are still common in the field, it would perhaps be useful to address these concerns in the text, and if data are available that do not have these potential confounds those could be included as well.

We thank the reviewer for the suggestion and acknowledge that the practice of using FUDR as part of lifespan and other experiments is not ideal. We have amended the text further to address this concern, and in addition added the following to the Discussion section:

"Many of the described experiments used FUDR, a chemical inhibitor of thymidine synthesis, to block the production of progeny. While the actions of FUDR in postmitotic adult *C. elegans* are thought to act primarily in the germline to inhibit DNA replication in the dividing germ cells, there is also evidence that FUDR can act in somatic tissue and can lead to complex interactions with various genes and treatments in the regulation of lifespan (Anderson et al., 2016). As such, we chose a relatively small dose (40 mM) to use for our experiments, and importantly, verified key findings in lifespan experiments that did not use FUDR."

> In particular, this reviewer noted that FUDR enhances the effects of mitochondrial double mutants (fzo/drp) from your prior work and wonders if the use of FUDR could be impacting outcomes in the current study.

We are unclear what data the reviewer is referring to here. Indeed, in the paper cited (Weir et al., 2017), we performed lifespans of *fzo-1* mutants with and without FUDR and saw little difference between with FUDR and without. As seen previously by us and others, lifespans on HT115 with carb are longer lived than those on OP50 without antibiotics. Therefore, we do not know the result being referred to by the reviewer 'that FUDR enhances the effects of the *fzo-1; drp-1*

double mutant'.

However, we also note that we have replicated the key FZO-1 experiment in this study demonstrating that the mitochondrial fusion mutant *fzo-1* blocks *raga-1* lifespan both with and without using FUDR, suggesting it is not an artifact or some complex interaction caused by FUDR use (compare Figure 5A, Figure 5---figure supplement 1). In addition, all of the experiments we conducted using the single copy knock-in strains (lifespans, body size determination, developmental delay) were done without the use FUDR.
